The opinion of the people selling the product, the product the public have funded the purchase of to the degree that there are millions of surplus doses, should not be considered when determining whether the product is appropriate or fit for purpose.Seems like ATAGI doesn't agree with you.
The primary benefit of the vaccines have always been to minimize the hospitalization rate. They have been sold to people as preventing transmission, to protect grandma, but it's always been designed that they keep you out of hospital as much as possible.
We currently have vaccine producers advocating more of their product, on segments they sponsor in the media, to gain momentum to push governments to spend more money using alpha variant products on a new omicron variant before they had any data on the variant.
This is while they have had a delta variant specific booster for months.